Loading...
Nivolumab combined with FOLFOX is approved for first-line treatment of metastatic gastroesophageal adenocarcinoma. Prior trials have shown improvements in progression-free survival (PFS), overall survival (OS), and response rate in patients with PDL-1 combined positive scores (CPS) ≥5%, with no clear survival benefit in patients with CPS <5% to 10%.
Investigators now report findings from ATTRACTION-4, an industry-sponsored, double-blind, placebo-controlled trial conducted in Asia that evaluated the addition of nivolumab to first-line S-1 or capecitabine plus oxaliplatin chemotherapy in patients with HER2-negative metastatic gastric cancer. Of 724 patients, 29% had prior gastrectomy, 18% received perioperative chemotherapy, 51% had diffuse ca…